

# Vincenza Calvaruso

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2532054/vincenza-calvaruso-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

3,917  
citations

35  
h-index

59  
g-index

166  
ext. papers

4,755  
ext. citations

4.2  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
121	Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. <i>Hepatology</i> , <b>2009</b> , 49, 1236-44	11.2	202
120	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , <b>2018</b> , 155, 411-421.e4	13.3	201
119	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2417-2429	40	176
118	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 485-493	13.4	160
117	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 2112-20	0.7	148
116	Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1994-2000	15.4	145
115	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , <b>2016</b> , 151, 130-139.e2	13.3	107
114	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 688-695	6.1	104
113	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. <i>Liver International</i> , <b>2011</b> , 31, 730-9	7.9	92
112	Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 699-709	3.4	88
111	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 484-91	13.4	84
110	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1217-23	13.4	84
109	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 2-8	7.9	83
108	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 265-273	13.4	80
107	RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1639-47	4	79
106	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 878-885	13.4	75
105	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , <b>2017</b> , 37, 514-528	7.9	71

104	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 18-24	13.4	68
103	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 867-74	3.4	67
102	TACE versus TAE as therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 1623-41	3.5	65
101	Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. <i>Liver Transplantation</i> , <b>2011</b> , 17, 178-88	4.5	62
100	Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 84-92	6.9	51
99	Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 1227-32	4	50
98	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 962-8	13.4	48
97	Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. <i>Liver International</i> , <b>2014</b> , 34 Suppl 1, 85-90	7.9	47
96	Coagulation and fibrosis in chronic liver disease. <i>Gut</i> , <b>2008</b> , 57, 1722-7	19.2	47
95	Impact of tips preliver transplantation for the outcome posttransplantation. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 192-200	8.7	46
94	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 476-9	4.5	45
93	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , <b>2015</b> , 8, 1037-46	4.1	42
92	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
91	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , <b>2012</b> , 97, 679-86	6.6	41
90	Prospective comparison of Fibroscan, KingQ score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 546-54	3.4	39
89	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1109-1116	13.4	39
88	An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 769-74	3.4	37
87	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , <b>2020</b> , 296, 40-47	3.1	36

86	Implication of normal liver enzymes in liver disease. <i>Journal of Viral Hepatitis</i> , <b>2009</b> , 16, 529-36	3.4	34
85	HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 72-79	3.4	33
84	Clinical implications of the hyperdynamic syndrome in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 795-802	3.9	33
83	The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 921-9	6.9	32
82	Is global elimination of HCV realistic?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 40-46	7.9	30
81	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , <b>2017</b> , 37, 1526-1534	7.9	29
80	Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1335-1345	4	29
79	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 310-317	3.3	29
78	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185728	3.7	28
77	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2408-2418	6.7	28
76	Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 504-8	3	25
75	A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2017</b> , 21, 112-121	2.9	25
74	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 597-600	13.4	23
73	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
72	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 16-21	13.4	23
71	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 143-8	3.3	23
70	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 469-74	3.4	23
69	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1275-1282	0.7	23

68	Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, 83-89	3.9	22
67	A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 640-9	3.4	22
66	Immunological alterations in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8916-23	5.6	22
65	Hepatic benefits of HCV cure. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1548-1556	13.4	22
64	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1705-1712 <sup>21</sup>	6.1	21
63	NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e68364	3.7	20
62	Fibrosis in chronic viral hepatitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 219-30	2.5	20
61	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 603-13	6.1	20
60	Why do I treat my patients with mild hepatitis C?. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 7-12	7.9	19
59	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 113-21	3.4	16
58	Pegylated-interferon-(2a) in clinical practice: how to manage patients suffering from side effects. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 429-35	4.1	15
57	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 731-741	3.3	14
56	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14
55	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. <i>Liver International</i> , <b>2016</b> , 36, 1765-1773	7.9	14
54	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
53	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , <b>2015</b> , 2015, 431750	3.4	13
52	Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40, 794-9	3.3	13
51	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110857	3.7	13

50	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 477-86	6.1	12
49	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 739-50	5.1	12
48	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 801-810	13.4	12
47	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177352	3.7	11
46	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 340-349	13.4	11
45	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B antigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 118-124	3.4	11
44	Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. <i>Hepatitis Monthly</i> , <b>2013</b> , 13, e7176	1.8	10
43	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 790-800	3.4	10
42	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100248	10.3	10
41	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , <b>2011</b> , 60, 1023	19.2	9
40	Histological subclassification of cirrhosis. <i>Hepatology</i> , <b>2010</b> , 52, 804-5	11.2	9
39	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , <b>2020</b> , 40, 2820-2827	7.9	9
38	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13165	3.8	9
37	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 818-25	3.3	8
36	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , <b>2015</b> , 82, 48-52	3.6	8
35	Models for non-alcoholic fatty liver disease: a link with vascular risk. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 378-84	3.3	8
34	Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 6861-4	5.6	8
33	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , <b>2021</b> , 41, 1802-1814	7.9	8

32	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 572-581	13.4	8
31	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , <b>2019</b> , 9, 585	4.9	6
30	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 469-80	3.4	6
29	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 650-5	3.3	6
28	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 117-138	4.3	5
27	Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human?. <i>Gut</i> , <b>2010</b> , 59, 709-10	19.2	4
26	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , <b>2022</b> , 11, 75-84	9.1	4
25	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Name Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , <b>2021</b> , 74, 1496-1508	11.2	4
24	Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S83	13.4	4
23	Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S23-S24	13.4	3
22	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, e60	3.3	3
21	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). <i>Liver International</i> , <b>2019</b> , 39, 2240-2243	7.9	3
20	Critically ill patients with cirrhosis and low serum sodium. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 523-4; author reply 524-5	3	3
19	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1190-1199	3.4	3
18	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , <b>2019</b> , 47, 409-415	5.8	3
17	Hepatocellular carcinoma and direct-acting antivirals: A never ending story?. <i>Liver International</i> , <b>2017</b> , 37, 812-814	7.9	2
16	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, e59	3.3	2
15	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , <b>2015</b> , 10, 977-88	2.9	2

14	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1301-1307	3.3	2
13	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , <b>2020</b> , 40, 530-538	7.9	1
12	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , <b>2021</b> , 41, 2179-2188	7.9	1
11	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S625-S626	13.4	
10	P114 A screening tool for the early diagnosis of extraintestinal manifestations in inflammatory bowel disease: the EMAIL questionnaire. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S192-S193	1.5	
9	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 58	3.3	
8	P522 Expression of markers of early atherosclerosis in inflammatory bowel disease: a prospective cohort of a single referral centre. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S373-S374	1.5	
7	PTU-059 Which correlation among histological assessment of fibrosis, non-invasive markers and portal hypertension in HCV transplanted patients?. <i>Gut</i> , <b>2010</b> , 59, A72.2-A73	19.2	
6	Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.. <i>Blood</i> , <b>2008</b> , 112, 1826-1826	2.2	
5	Extrahepatic Manifestations of Chronic HCV <b>2012</b> , 61-73		
4	P228 Cytomegalovirus Infection: is it a cause of flare-up in inflammatory bowel diseases?. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S256-S257	1.5	
3	P293 Loss of response after first-line biologic therapy in patients with inflammatory bowel disease: practical approach and management. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S299-S299	1.5	
2	Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 969	13.4	
1	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1603-1609	3.3	